Skip to main content
Fig. 3 | BMC Surgery

Fig. 3

From: Significance of postoperative adjuvant chemotherapy with an oxaliplatin-based regimen after simultaneous curative resection for colorectal cancer and synchronous colorectal liver metastasis: a propensity score matching analysis

Fig. 3

Comparisons of recurrence-free (RFS), cancer-specific (CSS), unresectable recurrence-free (URRFS), remnant liver recurrence-free (RLRFS), and extrahepatic recurrence-free (EHRFS) survival in the propensity-matched cohort. RFS was significantly better among patients in the L-OHP (+) group compared with the L-OHP (−) group (HR 0.40, 95% CI 0.17–0.96, p = 0.04). In addition, there was a trend towards better RLRFS among patients in the L-OHP (+) group compared with the L-OHP (−) group (HR 0.42, 95% CI 0.17–1.02, p = 0.055). CSS (HR: 0.62, 95% CI 0.23–1.68, p = 0.35), URRFS (HR 0.63, 95% CI 0.26–1.55, p = 0.32), and EHRFS (HR 0.66, 95% CI 0.25–1.73, p = 0.40) did not differ significantly between the two groups

Back to article page